Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

VOYAGER THERAPEUTICS, INC.

(VYGR)
  Report
Delayed Nasdaq  -  04:00 2022-11-28 pm EST
5.570 USD   +1.09%
11/08Transcript : Voyager Therapeutics, Inc., Q3 2022 Earnings Call, Nov 08, 2022
CI
11/08Voyager Therapeutics : Q3 Earnings Snapshot
AQ
11/08VOYAGER THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Voyager Therapeutics : Statement of Changes in Beneficial Ownership - Form 4

09/21/2022 | 04:50pm EST
Ownership Submission
FORM 4
Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287Expires:January 31, 2005Estimated average burden hours per response...0.5
1. Name and Address of Reporting Person *
PFREUNDSCHUH PETER P.
2. Issuer Name and Ticker or Trading Symbol
Voyager Therapeutics, Inc. [VYGR]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
Chief Financial Officer /
(Last) (First) (Middle)
C/O VOYAGER THERAPEUTICS, INC., , 64 SIDNEY STREET
3. Date of Earliest Transaction (Month/Day/Year)
(Street)
CAMBRIDGE MA 02139
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Join/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code 4. Securities Acquired (A) or Disposed of (D) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) 6. Ownership Form: Direct (D) or Indirect (I) 7. Nature of Indirect Beneficial Ownership
Code V Amount (A) or (D) Price
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code 5. Number of Derivative Securities Acquired (A) or Disposed of (D) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security 8. Price of Derivative Security 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) 11. Nature of Indirect Beneficial Ownership
Code V (A) (D) Date Exercisable Expriation Date Title Amount or Number of Shares
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
PFREUNDSCHUH PETER P.
C/O VOYAGER THERAPEUTICS, INC.,
64 SIDNEY STREET
CAMBRIDGE, MA02139


Chief Financial Officer
Signatures
/s/ Robert Hesslein, as Attorney-in-Fact for Peter P. Pfreundschuh 2022-09-21
**Signature of Reporting Person Date
Explanation of Responses:
(*) If the form is filed by more than one reporting person, see Instruction 5(b)(v).
(**) Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) This stock option was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4).
(2) The vesting commencement date of the option is the grant date. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting upon the one-year anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service as an employee.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Disclaimer

Voyager Therapeutics Inc. published this content on 21 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 September 2022 20:49:08 UTC.


ę Publicnow 2022
All news about VOYAGER THERAPEUTICS, INC.
11/08Transcript : Voyager Therapeutics, Inc., Q3 2022 Earnings Call, Nov 08, 2022
CI
11/08Voyager Therapeutics : Q3 Earnings Snapshot
AQ
11/08VOYAGER THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
11/08Voyager Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/08Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results
AQ
11/01Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
AQ
10/19Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
10/18Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
10/12Voyager Therapeutics Presents Data Characterizing a Novel CNS Receptor and Demonstratin..
AQ
10/12Voyager Therapeutics : Dose-response Evaluation of 9P801, an Engineered AAV Capsid with Hi..
PU
More news
Analyst Recommendations on VOYAGER THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 44,5 M - -
Net income 2022 -46,5 M - -
Net cash 2022 144 M - -
P/E ratio 2022 -4,63x
Yield 2022 -
Capitalization 215 M 215 M -
EV / Sales 2022 1,59x
EV / Sales 2023 -0,77x
Nbr of Employees 101
Free-Float 85,3%
Chart VOYAGER THERAPEUTICS, INC.
Duration : Period :
Voyager Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VOYAGER THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 5,57 $
Average target price 7,60 $
Spread / Average Target 36,4%
EPS Revisions
Managers and Directors
Alfred W. Sandrock President, Chief Executive Officer & Director
Peter P. Pfreundschuh Chief Financial & Accounting Officer
Michael J. Higgins Chairman
Todd Carter Chief Scientific Officer
Robin Swartz Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
VOYAGER THERAPEUTICS, INC.103.32%213
MODERNA, INC.-30.55%67 769
IQVIA HOLDINGS INC.-22.03%40 859
LONZA GROUP AG-33.93%39 445
ALNYLAM PHARMACEUTICALS, INC.23.36%26 171
SEAGEN INC.-21.59%22 918